A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX — GATTEX KAB

Short Bowel Syndrome (SBS) Clinical Trial

Official title:
Quantitative Testing of Patient and Prescriber Knowledge, Attitudes, and Behavior About GATTEX (Teduglutide) for Injection Safety and Use Information

Status Recruiting

Clinical Trial Summary

The main aim of this study is to document the level of knowledge and assess attitudes and behaviors of both participants and physicians regarding the risks and safe use of GATTEX. The survey will be done via internet, telephone, or paper and patients will be able to choose the method that is preferred. No study medicines will be provided to patients in this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05561647
Study type	Observational
Source	Takeda
Contact	Takeda Contact
Phone	+1 866 842 5335
Email	ClinicalTransparency@takeda.com
Status	Recruiting
Phase
Start date	August 1, 2013
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05371028` - A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
Completed	`NCT01674478` - Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies	Phase 2
Completed	`NCT05113082` - Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil